Menu
Recruiting NCT07312994

Analysis of NfL and GFAP in Different Dietary Patterns

— Observational Neurofilament Light Chain Glial Fibrillary Acidic Protein GFAP Vegan Diet

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP, Vegan Diet. Basic parameters: 18 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Austria
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Vegan, Vegeratian, or Omnivore: Dietary Effects on the Brain Tissue Biomarkers

Overview

This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP. The primary research question is: Do vegan, vegetarian, or omnivorous diets influence NfL and GFAP levels?

Primary outcome measures

  • Blood levels of the following biomarkers: neurofilament light chain (NfL) in pg/mL, glial fibrillary acidic protein (GFAP) in pg/mL. [Time frame: Once at baseline]

Eligibility criteria

Inclusion criteria

  • Healthy individuals who have followed a vegan, vegetarian, or omnivorous diet for at least one consecutive year
  • Aged between 18 and 40 years
  • Provision of written informed consent

Exclusion criteria

  • Diagnose neurological disorders (e.g. neurodegenerative, inflammatory, autoimmune, infectious, vascular)
  • Eating disorders
  • Excessive alcohol consumption
  • Pregnancy
  • Recent moderate to severe infection (within the past 12 weeks) , including SARS-CoV-2
  • Recent trauma, injury, or surgery (within the past 12 weeks)
  • Significant BMI fluctuations (>5 points) within the last year
  • Patients who have been using Proton pump inhibitors (PPIs) for an extended period (e.g., 1 month).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Other

Study locations

Austria · 1 center
  • Christian-Doppler-Klinik — Salzburg

Identifiers

NCT: NCT07312994 · 1119/2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗